More recently, several investigations have focused on the impact of mutations of the FLT3 gene in APL [2,3,5,7,9-11,35] that has been a well recognized adverse prognostic factor in AML with a normal karyotype. The gene discussed is FLT3; the disease is acute promyelocytic leukemia.